• 15 confirmed partial responses recorded in ongoing Phase 1b/2a ACCENT trial
• Narmafotinib combined with chemotherapy is superior to chemotherapy alone
• ACCENT trial evaluating narmafotinib in combination with gemcitabine and Abraxane in advanced pancreatic cancer

Amplia Therapeutics Limited (ASX: ATX) has announced important new data from its ongoing ACCENT clinical trial in pancreatic cancer. The trial is investigating the company's FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Fifteen confirmed partial responses have now been recorded in the trial, a level of response sufficient to demonstrate that the combination of narmafotinib and chemotherapy is superior to chemotherapy alone. The ACCENT trial is an open-label study, and the data is compared to historical data for the combination of gemcitabine and Abraxane. A total of 55 advanced pancreatic patients have enrolled in the study since January 2024, with 21 patients still on study at this time. The drug continues to be well tolerated by patients, with the rate and type of adverse events for the narmafotinib combination being similar to that reported for chemotherapy alone. Amplia is extremely excited to have recorded 15 confirmed partial responses, demonstrating the benefit of adding narmafotinib to standard-of-care chemotherapy, and is hopeful that further partial responses will be observed as the trial continues.

The company has not provided any high-importance, price-sensitive forward-looking financial metrics or other company-specific metrics in the announcement.

The company has not provided any forward-looking outlook in the announcement.